SCHEMBL18220199

SCHEMBL18220199

COCCNC(=O)/C(C#N)=C(\C)c1ccc(-c2ccc3cc(N(C)C)ccc3c2)n1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.36
KMT2A Q03164 6/20 0.36
LMNA P02545 5/20 0.36
MEN1 O00255 5/20 0.36
HPGD P15428 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPK1 P28482 2/20 0.36
MITF O75030 1/20 0.36
MDM2 Q00987 1/20 0.36
EGLN2 Q96KS0 1/20 0.35
HTT P42858 2/20 0.34
KDM4E B2RXH2 6/20 0.33
MAPT P10636 4/20 0.33
NPC1 O15118 1/20 0.33
NFKB1 P19838 1/20 0.33
RAB9A P51151 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
POLB P06746 1/20 0.32
GAA P10253 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18220211 0.91 LMNA (0.35) ALDH1A1KMT2ALMNAMEN1HPGD
SCHEMBL21226386 0.91 SCN9A (0.36) ALDH1A1KMT2ALMNAMEN1KDM4E
SCHEMBL18220203 0.90 LMNA (0.34) ALDH1A1KMT2ALMNAMEN1HPGD
SCHEMBL18220226 0.83 DHODH (0.32)
SCHEMBL17120848 0.83
SCHEMBL18220197 0.83 APP (0.42) ALDH1A1KMT2ALMNAMEN1HPGD
SCHEMBL18220206 0.83 APP (0.44) ALDH1A1KMT2AMEN1EGLN2KDM4E
SCHEMBL18220196 0.82 APP (0.44) ALDH1A1KMT2ALMNAMEN1HPGD
SCHEMBL18220214 0.82 KDM4E (0.31) ALDH1A1LMNAHPGDSMN1; SMN2KDM4E
SCHEMBL18220002 0.81 LMNA (0.43) ALDH1A1KMT2ALMNAMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-20210371390-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2021-12-02 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 ALDH1A1 4151/4885KMT2A 4649/4885LMNA 1263/4885
US-20210371390-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 ALDH1A1 4151/4885KMT2A 4649/4885LMNA 1263/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 ALDH1A1 4151/4885KMT2A 4649/4885LMNA 1263/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA ALDH1A1 4226/4885KMT2A 4621/4885LMNA 1283/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA ALDH1A1 4226/4885KMT2A 4621/4885LMNA 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.